MET and adenocarcinoma: Their analysis revealed heightened c-Met protein expression in NSCLC patients, particularly in adenocarcinoma cases, and established a connection between c-Met protein overexpression and poorer prognosis and lower survival rates in adenocarcinoma patients [20].